Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.

It was a rock star during the coronavirus pandemic, but Pfizer (NYSE: PFE) hasn't been the most exciting company in 2024. Its stock has become something of a value play, at least according to one analyst who released a fresh research note based on meetings with company management. He feels the stock has upside potential that's comfortably in the double-digit percentages. Here's why.BMO Capital's Evan David Seigerman recently reiterated his outperform (i.e., buy) recommendation on Pfizer. He also maintained his $36-per-share price target on the well-known healthcare stock, which anticipates a gain of nearly 20% over the next 12 months. The meetings that led to the recommendation came in the form of non-deal roadshows hosted by BMO that included private conferences between company managers and institutional investors.Of these, Seigerman wrote, "We came away from the meetings with a sense of motivated self-awareness," on Pfizer's part. He feels the company has a sensible strategy to regain its footing somewhat after the years of the COVID-19 pandemic when Comirnaty (co-developed with German peer BioNTech) was a vaccine used to fight the disease.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool